Nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease
Conditions
Interventions
Intervention 1: Intervention group: 1st group (interventional group) was instructed to eat the conventional diet combined with 200 mg/kg bw/day of J.sambac in the form of salad,. Intervention 2: Contr
Sponsors
Ali –Ul- Murtaza Department of Rehabilitation Science, MIMAS
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Participants in the study were to be 23 to 77 years old Body mass index >25 kg/m2 Participants diagnosed with NAFLD as determined by an ultrasound examination
Exclusion criteria
Exclusion criteria: Following a weight reduction diet in the three months earlier Anti-diabetic, anti-hyperlipidemic, and anti-hypertensive drugs Past stroke Cardiomyopathy Diabetes Retinal disorder Stomach ulcers Kidney stones Using other drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood sugar (FBS). Timepoint: 3 months. Method of measurement: Venous blood samples willbe taken at the start and completion of the trial.;Triglycerides (TG). Timepoint: 3 months. Method of measurement: Venous blood samples will be taken at the start and completion of the trial and then evaluated using an enzymatic colorimetric assay utilizing commercial kits (Pars Azmoon).;Total cholesterol (TC), LDL cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). Timepoint: 3 months. Method of measurement: Venous blood samples will be taken at the start and completion of the trial and then evaluated using an enzymatic colorimetric assay utilizing commercial kits (Pars Azmoon). After apolipoprotein B-containing lipoproteins were precipitated using chloride magnesium and dextran sulphate as part of the oxidase cholesterol technique, serum HDL and LDL cholesterol levels were measured.;ALT(alanine transaminase), AST (aspartate aminotransferase), ALP (alkaline phosphatase) , LDH (lactate dehydrogenase). Timepoint: 3 months. Method of measurement: Venous blood samples will be taken at the start and completion of the trial.;Total antioxidant capacity. Timepoint: 3 months. Method of measurement: Assessed by using 2,2-diphenyl-1-picrylhydrazyl (DPPH).;Platelet aggregation and platelet activation. Timepoint: 3 months. Method of measurement: Platelet aggregation was evaluated using impedance aggregometry, and platelet activation was assessed using flow cytometry.;Inflammation. Timepoint: 3 months. Method of measurement: Inflammation measured by check the CRP level. | — |
Secondary
| Measure | Time frame |
|---|---|
| Systolic (SBP) and diastolic blood pressure(DBP). Timepoint: 3 months. Method of measurement: Sphygmomanometer. | — |
Countries
Pakistan
Contacts
Public ContactHifza Arif
Ali –Ul- Murtaza Department of Rehabilitation Science, MIMAS
Outcome results
None listed